First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Intismeran autogene’s Interpath-001 trial reads out this year.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
